Cogent Biosciences (COGT) to Announce Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Cogent Biosciences to post earnings of ($0.55) per share and revenue of $0.0010 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53). On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cogent Biosciences Stock Down 3.5%

Shares of NASDAQ:COGT traded down $1.41 during trading on Tuesday, hitting $39.03. 133,213 shares of the company’s stock traded hands, compared to its average volume of 2,249,690. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $36.04 and a 200-day moving average price of $36.39. Cogent Biosciences has a 52 week low of $10.38 and a 52 week high of $43.73. The company has a market cap of $6.67 billion, a price-to-earnings ratio of -18.00 and a beta of 0.34.

Institutional Investors Weigh In On Cogent Biosciences

A number of large investors have recently bought and sold shares of COGT. Invesco Ltd. raised its position in shares of Cogent Biosciences by 57.3% in the 4th quarter. Invesco Ltd. now owns 585,765 shares of the technology company’s stock valued at $20,806,000 after buying an additional 213,495 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Cogent Biosciences during the 4th quarter worth approximately $318,000. Voloridge Investment Management LLC bought a new position in Cogent Biosciences in the fourth quarter valued at approximately $23,762,000. Squadron Capital Management LLC acquired a new position in Cogent Biosciences during the fourth quarter valued at approximately $27,706,000. Finally, Wellington Management Group LLP lifted its stake in Cogent Biosciences by 566.6% during the fourth quarter. Wellington Management Group LLP now owns 2,712,336 shares of the technology company’s stock worth $96,342,000 after purchasing an additional 2,305,437 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COGT. Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 29th. HC Wainwright lifted their price target on shares of Cogent Biosciences to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cogent Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $45.90.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.